Home | Cancers | Breast Cancer

Breast Cancer

Combination drug therapy doubles positive effect of treatment for women with advanced breast cancer

UCLA study shows that combining palbociclib with letrozole holds promise for women with estrogen receptor-positive breast cancer ...

Study shows how breast cancer cells break free to spread in the body

More than 90 percent of cancer-related deaths are caused by the spread of cancer cells from their primary tumor site to other ...

New breast cancer classification based on epigenetics

Image of a breast tumor identified as Epi-Luminal B of poor prognosis. ... Full story

U.Va. Study Finds Breast Density Helps Predict Breast Cancer Risk

A new study from the University of Virginia Cancer Center has found that adding a measurement of breast density better predicts women’s risk for breast cancer. ... Full story

Breast Cancer Specialist Presents Positive Results for Triple-Negative Breast Cancer Presurgery Chemotherapy Benefits

A breast cancer specialist and clinical researcher at Women & Infants Hospital of Rhode Island presented research yesterday at the 2014 San Antonio Breast Cancer Symposium showing that adding either the chemotherapy drug carboplatin or the blood vessel-targeting drug bevacizumab to the standard treatment of chemotherapy before surgery helped women who have the basal-like subtype of triple-negative breast cancer. ... Full story

Multigene Test Can Predict Risk of Disease Recurrence for Women With Ductal Carcinoma in Situ

SAN ANTONIO — A multigene test called Oncotype DX DCIS Score (DCIS Score) was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), a noninvasive breast abnormality, according to data from a large, population-based study presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13. The test could provide important individualized information on the risk of recurrence after treatment by breast-conserving surgery, which can help better inform physicians and patients on their future risks and the need for additional treatment. ... Full story

Fulvestrant Improves Survival Over Anastrozole for Patients With Advanced Breast Cancer

SAN ANTONIO — Among patients with advanced, hormone receptor-positive breast cancer who had not been treated previously for advanced disease, those who took fulvestrant lived longer than those who took anastrozole, according to data from the phase II FIRST trial presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13. John Robertson, MD ... Full story

Sprague Study Shows Supplemental Breast Cancer Screening for Women with Dense Breasts Not Beneficial

Findings Could Impact Pending Breast Density Notification Legislation ... Full story

New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years

The preventive effect of breast cancer drug ‘tamoxifen’ remains virtually constant for at least 20 years – with rates reduced by around 30 per cent – new analysis published in The Lancet Oncology reveals. ... Full story

Impact of Adding Bevacizumab to Presurgery Chemo for Triple-negative Breast Cancer Varies With Subtype

​SAN ANTONIO — Among women with triple-negative breast cancer, the benefit of adding bevacizumab to standard presurgery chemotherapy was greater for those whose cancers were classified as basal-like by gene expression assay compared with those whose cancers were nonbasal-like, according to data presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 9–13. In contrast, the benefit of adding carboplatin was equivalent across subtypes. ... Full story

1 2 3 4 5 6 7 8 9 10 next last total: 450 | displaying: 1 - 10